ReviewImmunotherapy2014
Optimizing NKT cell ligands as vaccine adjuvants.
Review in Immunotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- DODAB-ODN lipoplex structure is highly dependent on ODN concentration: A multitechnique experimental study.Biochemistry and biophysics reports · 2025Article
- Article
- Vaccine therapies for glioma: clinical frontiers and potential breakthrough.Frontiers in oncology · 2025Review
- Optimizing iNKT-driven immune responses against cancer by modulating CD1d in tumor and antigen presenting cells.Clinical immunology (Orlando, Fla.) · 2024Review
- Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies.Frontiers in immunology · 2024Review
- Natural Killer T Cell Diversity and Immunotherapy.Cancers · 2023Review
- Semisynthetic Pneumococcal Glycoconjugate Nanovaccine.Bioconjugate chemistry · 2023Article
- Development of virus-like particles with inbuilt immunostimulatory properties as vaccine candidates.Frontiers in microbiology · 2023Article
- Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model.Cancer immunology, immunotherapy : CII · 2022Article
- Gut Microbiota-Derived Unconventional T Cell Ligands: Contribution to Host Immune Modulation.ImmunoHorizons · 2022Article
- The NKT cell TCR repertoire can accommodate structural modifications to the lipid and orientation of the terminal carbohydrate of iGb3.RSC advances · 2022Article
- Efficient synthesis of α-galactosylceramide and its C-6 modified analogs.Frontiers in chemistry · 2022Article
- Peripheral immune tolerance by prolactin-induced protein originated from human invariant natural killer T cells.Bioengineered · 2021Article
- Obesity and severe coronavirus disease 2019: molecular mechanisms, paths forward, and therapeutic opportunities.Theranostics · 2021Review
- Use of aFrontiers in immunology · 2021Article
- Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action.Nature reviews. Chemistry · 2021Review
- The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.International journal of nanomedicine · 2021Article
- Advances in Oral Subunit Vaccine Design.Vaccines · 2020Review
- Contribution of NKT cells to the immune response and pathogenesis triggered by respiratory viruses.Virulence · 2020Article
- Modulation of Immune Responses to Influenza A Virus Vaccines by Natural Killer T Cells.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
NKT cells are a subpopulation of T lymphocytes with phenotypic properties of both T and NK cells and a wide range of immune effector properties. In particular, one subset of these cells, known as invariant NKT cells (iNKT cells), has attracted substantial attention because of their ability to be specifically activated by glycolipid antigens presented by a cell surface protein called CD1d. The development of synthetic α-galactosylceramides as a family of powerful glycolipid agonists for iNKT cells has led to approaches for augmenting a wide variety of immune responses, including those involved in vaccination against infections and cancers. Here, we review basic, preclinical and clinical observations supporting approaches to improving immune responses through the use of iNKT cell-activating glycolipids. Results from preclinical animal studies and preliminary clinical studies in humans identify many promising applications for this approach in the development of vaccines and novel immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.